Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Orion stock climbs to record high after positive Nubeqa data and analyst upgrade

Orion jumped after a data update on darolutamide (Nubeqa) at ESMO, because the drug clearly reduced the risk of metastasis or death in prostate cancer patients. Barclays sees the data as a tailwind for use in earlier stages, and Jefferies upgraded Orion from hold to buy and raised the price target significantly. The stock rose in Helsinki by around five percent to just under €98 and has been substantially up since mid‑August 2024. » Mere på deraktionaer.de
Orion raises forecast for 2026 after stronger licensing revenues

Orion raises its revenue and EBIT forecast for 2026 and now expects net sales of €2.07–2.14 billion and an operating result of €730–790 million. The reason is higher-than-expected licensing revenues in the first nine months, mainly due to the success of Nubeqa, which is licensed to Bayer. The share price climbs to a record level near €90; analysts and investors are likely to further adjust price targets and positions. » Mere på deraktionaer.de
Orion rises to new record high thanks to Nubeqa growth

Orion is benefiting significantly from strong sales of the prostate cancer drug Nubeqa, which is licensed to Bayer and generates milestone payments as well as revenue shares. In the second quarter, revenue rose by about 25%, operating profit by around 69%, and the margin increased by 8.8 percentage points. The stock exceeded €85 for the first time; the third-quarter figures will be published on October 28. Since August 2024, the share price has gained nearly 90% (excluding dividends). » Mere på deraktionaer.de
Orion: strong half-year, outlook raised and stock hits 52-week high

Orion reported significantly better numbers for H1 2026: net sales in Q2 rose 25% year-on-year and operating profit increased 69%. The drivers were substantially higher licence revenues for Nubeqa, which is marketed jointly with Bayer. Management raised the full-year guidance for net sales to €2,000–2,100m and for operating profit to €650–750m. The combination of the earnings beat and the outlook upgrade pushed the stock up 9.1% to €75 and to a new 52-week high. » Mere på de.investing.com
Orion raises guidance after strong quarter thanks to Nubeqa

Orion reports second-quarter sales up just over 25% to €521.6 million and EBIT up 70% to €175.8 million. Revenues from Nubeqa sales and milestone payments amounted to €236.8 million. Earnings per share were €1.00 and the guidance for 2026 was raised: revenue €2.00–2.10 billion (previously €1.95–2.10) and operating result €650–750 million (previously €600–750). The stock reacted with a price rise of around 9% to €75.00. » Mere på deraktionaer.de

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2026 har Orion B allerede udloddet 1,80 € i udbytte. Den seneste udlodning fandt sted i oktober.

Virksomhedstal

I det seneste kvartal havde Orion B en omsætning på 542,2 mio. € og et nettoresultat på 167,6 mio. €

(EUR)	september 2026	YoY
Omsætning	542,2 mio.	28,27 %
Bruttofortjeneste	365,5 mio.	44,07 %
Nettoresultat	167,6 mio.	74,58 %
EBITDA	224,4 mio.	66,10 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	14,46 mia. €
Antal aktier	140,37 mio.
Højeste/laveste i 52 uger	104,00 € - 58,85 €
Udbytteafkast	1,75 %
Udbytte TTM	1,80 €
Beta	0,28
P/E (PE Ratio)	22,01
PEG (PEG Ratio)	0,20
K/I (PB Ratio)	10,37
P/S (PS Ratio)	6,64

Virksomhedsprofil

Orion Oyj udvikler, fremstiller og markedsfører humane og veterinære lægemidler samt aktive farmaceutiske ingredienser (API'er) i Finland, Skandinavien, andre europæiske lande, Nordamerika og internationalt. Selskabet leverer receptpligtige lægemidler og selvbehandlingsprodukter, herunder Nubeqa til behandling af prostatakræft; dexdor og Precedex til intensiv sedation; Stalevo og Comtess/Comtan til Parkinsons sygdom; Simdax til akut dekompenseret hjertesvigt; og Fareston til brystkræft, samt lægemidlerne Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler og Buventol Easyhaler til behandling af astma og kronisk obstruktiv lungesygdom (KOL). Selskabet tilbyder desuden veterinærlægemidler, bl.a. Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo og Tessie; og API'er til generiske og proprietære lægemidler, ligesom det leverer kontraktfremstillingsydelser. Derudover markedsfører og sælger det veterinærlægemidler fremstillet af andre internationale virksomheder. Selskabet betjener forskellige sundhedsudbydere og fagfolk, såsom speciallæger og praktiserende læger, dyrlæger, apoteker, hospitaler, sundhedscentre, klinikker og laboratorier, samt forbrugere med kæledyr. Orion Oyj har et partnerskab med Propeller Health for at forbinde Easyhaler®-produktporteføljen til behandling af astma og KOL; og et forsknings- og licenssamarbejde med Alligator Bioscience AB (publ) om at opdage og udvikle nye bispecifikke antistofbaserede kræftbehandlinger. Orion Oyj blev grundlagt i 1917 og har hovedsæde i Espoo, Finland.

Navn	Orion B
CEO	Aino Anna Liisa Hurme
Hjemsted	Espoo, uu Finland
Websted	is.gd/3PivOU
Sektor	Sundhed
Branche	Sundhedsudbydere og -tjenester
Børsnotering	07.10.2004
Medarbejdere	4.215